Anti-Viral Treatment With Pertussis Toxin B Oligomer
OwnerMIchael Bukrinsky, Massimo Alfanoinventors
Life of this patent
Estimating the term…
Abstract
There is disclosed a method for anti-viral therapy, and for decreasing infectivity of viruses that use the chemokine CCR5 receptor as a co-receptor by treatment with the B. pertussis toxin (PTX) B oligomer, wherein the PTX B oligomer is composed of from two to ten subunits of PTX B oligomer selected from the group consisting of S2, S3, S4, S5, and combinations thereof.
Claims49
A method for treating viral infections, comprising administering an effective amount of B. pertussis toxin (PTX) B oligomer to a patient having a viral infection, wherein the PTX B oligomer comprises from two to ten subunits of PTX selected from the group consisting of S2, S3, S4, S5, and combinations thereof, and wherein the viral infection is inhibited by a mechanism selected from the group consisting of inhibition of viral entry into the cell, inhibition of post-entry replication, inhibition of co-capping of a viral receptor or co-receptor, desensitization of a viral receptor or co-receptor, modulation of protein kinase C (PKC) activity, and combinations thereof.
A method for decreasing the infectivity of a cell or susceptibility of a cell to retroviral infection, wherein the cell expresses a CCR5 chemokine receptor, and wherein a virus uses the CCR5 chemokine receptor as a co-receptor, comprising contacting the cell with an amount of B. pertussis toxin (PTX) B oligomer sufficient to induce an antiviral mechanism selected from the group consisting of inhibition of viral entry into the cell, inhibition of post-entry replication, inhibition of co-capping of a viral receptor or co-receptor, desensitization of a viral receptor or co-receptor, modulation of protein kinase C (PKC) activity, and combinations thereof.
A method for treating a CCR5 receptor-related physiological or pathological condition, comprising administering to a patient having the CCR5 receptor-related physiological or pathological condition, an amount of B. pertussis (PTX) B oligomer sufficient to desensitize the CCR5 receptor, wherein the PTX B oligomer is composed of from two to ten subunits of PTX selected from the group consisting of S2, S3, S4, S5, and combinations thereof.
A vaccine formulation for vaccinating against opportunistic infections from non-HIV pathogens in HIV-infected individuals, consisting essentially of an HIV-suppressing formulation of B. pertussis toxin (PTX) B oligomer (PTX B oligomer), an antigenic component specific for the non-HIV pathogen, with the proviso that the non-HIV pathogen is not influenza, and a vaccine-acceptable carrier.
A method for vaccinating against opportunistic infections from non-HIV pathogens in HIV-infected individuals, comprising administering an HIV-suppressing formulation of B. pertussis toxin (PTX) B oligomer (PTX B oligomer) and an antigenic component specific for the non-HIV pathogen.
A method for vaccinating to protect an individual against HIV infection in an individual not infected with HIV comprising administering a vaccine composition comprising B. pertussis toxin (PTX) B oligomer (PTX B oligomer) and an antigenic component specific for HIV.
An HIV preventive vaccine formulation consisting essentially of B. pertussis toxin B oligomer (PTX B oligomer), an antigenic component specific for HIV, and a vaccine-acceptable carrier.
A method for treating HIV infection, comprising administering B. pertussis toxin B oligomer (PTX B oligomer) in combination with an anti-HIV agent, wherein the HIV agent is selected from the group consisting of protease inhibitors, reverse transcriptase inhibitors, nuclear localization importation inhibitors, and combinations thereof.
A method for preventing HIV infection in an individual recently having transmissable contact with an HIV-infected individual, comprising administering B. pertussis toxin (PTX) B oligomer (PTX B oligomer) in combination with an agent selected from the group consisting a nuclear localization importation inhibitor, reverse transcriptase inhibitors, protease inhibitors, and combinations thereof.
A pharmaceutical composition for treating viral infections consisting essentially of PTX B oligomer and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.